74 citations
,
September 1980 in “Medical Clinics of North America” Toxic epidermal necrolysis is a severe skin condition often caused by drugs, with complex treatment and a high risk of death, but survivors usually heal without scars.
November 2023 in “Journal of cosmetic dermatology” The 595-nm pulsed dye laser effectively reduces symptoms of EFFC with minimal side effects.
1 citations
,
June 2021 in “Journal of dermatology and dermatitis” Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.
12 citations
,
January 2014 in “Journal of international medical research” Pemetrexed is as effective as docetaxel but has fewer side effects for treating nonsmall-cell lung cancer after EGFR-TKI therapy failure.
74 citations
,
February 2018 in “Journal of the American Academy of Dermatology” January 2024 in “Pharmaceutical journal/The pharmaceutical journal” Ritlecitinib can help about 14,000 people with severe hair loss.
November 2025 in “Journal of Investigative Dermatology” TEC kinases may help cause inflammation in vitiligo and could be targeted for treatment.
1 citations
,
April 2024 in “Clinical Medicine” Timely diagnosis and aggressive treatment with high-dose steroids and B-cell depletion therapies are effective for severe acute cutaneous lupus.
November 2025 in “Journal of Investigative Dermatology” Dithranol reduces inflammation in alopecia areata by lowering certain immune responses.
3 citations
,
February 2005 in “Lung Cancer” The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.
September 2025 in “The health sciences AUS.” Intralesional triamcinolone acetonide effectively treats acne keloidalis nuchae with minimal side effects.
3 citations
,
July 2024 in “Archives of Dermatological Research” Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
2 citations
,
May 2020 in “JAAD case reports” Ruxolitinib can cause a delayed skin reaction on the nose.
5 citations
,
September 2020 in “Proceedings - Baylor University. Medical Center” Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.
July 2021 in “International journal of dermatology, venereology and leprosy sciences” Diphenylcyclopropenone is more effective and has fewer side effects than dinitrochlorobenzene for treating alopecia areata.
1 citations
,
January 2023 in “Research Square (Research Square)” A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
1 citations
,
January 2024 in “Curēus” Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
8 citations
,
January 1977 in “Acta Haematologica” The treatment was effective for advanced non-Hodgkin's lymphomas.
July 2004 in “Journal of Clinical Oncology” Isolated limb perfusion is a safe and effective treatment for limb melanoma.
4 citations
,
January 2023 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
78 citations
,
May 2019 in “Frontiers in Cellular and Infection Microbiology” DPK-060 in poloxamer gel effectively treats skin infections, but nanocarriers don't enhance its efficacy.
14 citations
,
August 2017 in “International Journal of Immunopathology and Pharmacology” Photodynamic therapy improved skin issues from sorafenib when other treatments failed.
86 citations
,
November 2015 in “Journal of Gastroenterology” The NUDT15 R139C variant causes thiopurine-induced leukocytopenia through a different mechanism than previously thought in Japanese patients with inflammatory bowel disease.
12 citations
,
March 2021 in “JAAD Case Reports” Nail changes from immunotherapy can be managed without stopping cancer treatment.
33 citations
,
January 2018 in “Blood” Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.
February 2026 in “International Journal of Clinical Dermatology” A multi-drug treatment can effectively clear extensive calcinosis in juvenile dermatomyositis.
12 citations
,
May 2010 in “Journal of Clinical Oncology” MK-5108 is safe and shows potential against tumors, especially alone.
38 citations
,
April 2018 in “Diseases” L-PRF treatment helped heal diabetic foot ulcers effectively.
Ruxolitinib cream shows promise for vitiligo, and early melanoma diagnosis is crucial.
6 citations
,
October 2024 in “Journal of Family Medicine and Primary Care” Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.